COMPARATIVE INDICATORS OF SARCOPENIA IN PEOPLE WITH AND WITHOUT ONCOLOGICAL DISEASES ACCORDING TO X-RAY COMPUTED TOMOGRAPHY OF THE ABDOMINAL ORGANS
Abstract
The aim of the study was to compare CT indicators of sarcopenia in patients with and without cancer. Materials and methods. Two main indicators of sarcopenia, SMI (skeletal muscle index) and PMI (m. Psoas muscle index) were selected and studied. They were assessed using MSCT of the abdominal cavity at the level of the LIII vertebra. Results and conclusion. Comparing these indicators, it was found that using specific cut-off points, only the SMI proved to be statistically more reliable than the PMI, and therefore SMI is preferable for use in the diagnosis of sarcopenia. Since there are no standardized cut-off points for sarcopenia, it is impossible to definitely declare the failure of the PMI indicator directly. This result does not prove the impossibility of using the PMI criterion. The received indicators point the expediency of further studying the phenomenon of sarcopenia in cancer patients with a large sample. Nowadays, there is no wide-accepted method for radiological diagnosis of sarcopenia. Diagnosis of sarcopenia using CT is undoubtedly the most important step in reducing complications and improving the quality of treatment for both cancer and other diseases patients. Further search for CT indicators and their cut-off points is necessary for a more convenient and accurate diagnosis of sarcopenia.
References
Безденежный А.В., Сумин А.Н. Саркопения: распространенность, выявление и клиническое значение // Клиническая медицина. 2012. № 10. URL: https://cyberleninka.ru/article/n/sarkopeniya-rasprostranennost-vyyavlenie-i-klinicheskoe-znachenie
Дикова Т.С., Зацепина А.Ю., Федоринов Д.С., Лядов В.К. Саркопения, саркопеническое ожирение, миостеатоз как факторы неблагоприятного прогрноза при опузолях желудочно-кишечного тракта: обзор литературы // Современная онкология. 2021. № 1. URL: https://cyberleninka.ru/article/n/sarkopeniya-sarkopenicheskoe-ozhirenie-miosteatoz-kak-faktory-neblagopriyatnogo-prognoza-pri-opuholyah-zheludochno-kishechnogo
Закревский А.И., Фёдорова А.А., Пасечник И.Н., Кутепов Д.Е. Саркопения: как её диагностировать? // Клиническое питание и метаболизм. 2021. Т. 2, № 1. С. 13–22. DOI: https://doi.org/10.17816/clinutr71107.
Кукош М.Ю., Тер-Ованесов М.Д. Саркопения в практике онколога // Медицинский алфавит. 2018;1(15):37-43.
Сморчкова А.К., Петряйкин А.В., Семёнов Д.С., Шарова Д.Е. Саркопения: современные подходы к решению диагностических задач // Digital Diagnostics. 2022. Т. 3, № 3. С. 196−211. DOI: https://doi.org/10.17816/DD110721.
Хорошилов И.Е. Кахексия и саркопения у онкологических пациентов: диагностика и лечебная тактика // Клиническое питание и метаболизм. 2020;1(1):36–46. DOI: https://doi.org/10.36425/clinnutrit20650.
Хорошилов И.Е. Саркопения у больных: возможности диагностики и перспективы лечения // Лечащий врач. 2017. № 8. С. 32–35.
Jalal M, Campbell JA, Wadsley J, Hopper AD. Computed Tomographic Sarcopenia in Pancreatic Cancer: Further Utilization to Plan Patient Management //
J Gastrointest Cancer. 2021 Sep;52(3):1183-1187.
DOI: 10.1007/s12029-021-00672-4. Epub 2021 Jul 22. PMID: 34292498; PMCID: PMC8376713.
Ji Sun Kim, Won Young Kim, Hyun Kyung Park et al.; Simple Age Specific Cutoff Value for Sarcopenia Evaluated by Computed Tomography // Ann Nutr Metab 11 January 2018; 71 (3-4): 157–163. https://doi.org/10.1159/000480407
Prado CM, Antoun S, Sawyer MB. Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity // Curr. Opin. Clin. Nutr. Metab. Care. 2011; 14 (3): 250–254.
Report of the European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis // Age and Ageing 2010; 39: 412-423.
Tan Y, Duan T, Li B et al. Sarcopenia defined by psoas muscle index independently predicts long-term survival after living donor liver transplantation in male recipients // Quant Imaging Med Surg. 2022 Jan;12(1):215-228. DOI: 10.21037/qims-21-314. PMID: 34993073; PMCID: PMC8666738.
Trussardi Fayh AP, de Sousa IM Comparison of revised EWGSOP2 criteria of sarcopenia in patients with cancer using different parameters of muscle mass (2021) Comparison of revised EWGSOP2 criteria of sarcopenia in patients with cancer using different parameters of muscle mass // PLOS ONE 16(9): e0257446. https://doi.org/10.1371/journal.pone.0257446.
Xie H, Gong Y, Kuang J et al. Computed Tomography-Determined Sarcopenia Is a Useful Imaging Biomarker for Predicting Postoperative Outcomes in Elderly Colorectal Cancer Patients // Cancer Res Treat. 2020 Jul;52(3):957-972. DOI: 10.4143/crt.2019.695. Epub 2020 Apr 17. PMID: 32311863; PMCID: PMC7373859.
Yoneyama, Takeshi Numata, Kyoko Ota et al. Sarcopenia in Resected NSCLC: Effect on Postoperative Outcomes // Journal of Thoracic Oncology, Volume 13, Issue 7, 2018, Pages 895-903, ISSN 1556-0864, https://doi.org/10.1016/j.jtho.2018.04.035.73859.
